What Medtronic's latest 10-Q says: 4 signals
Medtronic filed its latest 10-Q with the SEC on Sep 3, 2026. It discusses compliance burden, digital transformation and goodwill impairment.
Public (MDT)Medical Equipment Manufacturing10,000+ employeesmedtronic.comLinkedIn
- Filed
- Sep 3, 2026
- Filings
- 2
- Signals
- 9
10-Q · latest 8
What Medtronic's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 4 signals
Medtronic's $19.7B Medical Surgical unit faces goodwill impairment risk, driving cost-cutting.
The unit's fair value exceeds its carrying value by only 12%, creating immense pressure for performance improvement and cost-saving initiatives.
$19.7B
Goodwill allocated to the Medical Surgical reporting unit at risk of impairment.
12%
Percentage by which the fair value of the Medical Surgical unit exceeds its carrying value.
Recent acquisitions of Scientia Vascular and SPR Therapeutics trigger system integration projects.
Medtronic's acquisitions in June and July 2026 will require significant post-merger integration, including the consolidation of disparate business systems.
Medtronic discloses regulatory filings with Russia's FSB for medical device imports.
The company must file notifications with Russia's Federal Security Service (FSB) to import medical devices with encryption, creating a complex compliance burden.
encryption
- SEC EDGAR
10-Q
Filed · 5 signals
The Medical Surgical reporting unit's fair value is only 12% above its carrying value, a narrow margin that exposes it to a potential multi-billion dollar goodwill impairment charge.
$19.8B
Goodwill allocated to the Medical Surgical reporting unit
12%
Fair value cushion above carrying value for the Medical Surgical unit
Medtronic confirms ongoing acquisition and investment strategy, signaling future M&A activity.
The company explicitly states that acquisitions and investment initiatives are a key part of its strategy.
Medtronic anticipates new product launches pending U.S. FDA and international regulatory approvals.
The company is expecting regulatory approvals for new products in the near future.
Company is focused on increasing its presence in markets outside the U.S.
Medtronic has a stated objective to expand into new markets, particularly outside the United States.
Medtronic highlights divestitures as a key strategic tool, signaling potential portfolio changes.
The company's forward-looking statements identify divestitures as a strategic option, indicating a focus on portfolio optimization.
Showing 8 of 9 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Medtronic earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Actively seeking more M&A deals to accelerate portfolio growth.Leadership has explicitly stated a new, more aggressive M&A strategy to acquire high-growth assets. This indicates available capital and active evaluation of targets, creating needs for M&A advisory, due diligence, and post-merger integration services. | |
| Launching multiple new products, including Hugo robot and new CGM sensorsThe company is in a major innovation cycle with several significant product launches planned, including the Hugo surgical robot in the U.S. and two new diabetes sensors. These launches require significant marketing, sales, and operational support, creating vendor opportunities. | |
| Diabetes business separation ('MiniMed') on track for completion.The planned spinoff of the Diabetes business into a new public company, MiniMed, is proceeding and expected to be complete within 15 months. This massive corporate carve-out will create massive vendor evaluation opportunities for both the new entity and the remaining Medtronic as they establish separate systems and operations. | |
| Winning share with AiBLE ecosystem, driving strong capital equipment salesMedtronic's AiBLE spine ecosystem is driving double-digit growth in capital equipment sales (Mazor, O-arm), with the CEO noting their capital is "growing like crazy" while competitors may be seeing softness. This success fuels further investment in the platform and integrated systems. | |
| Launching 'decisive urgent action' to improve efficiency and cut costs.A new, board-level Operating Committee is overseeing a corporate-wide push to improve efficiency in COGS and operating expenses. This creates a receptive environment for vendors with cost-saving solutions, automation, and operational consulting services. | |
| Planning Investor Day to unveil new long-term financial targets and strategyThe company will hold an investor day in mid-2026 to outline a new post-Diabetes separation strategy, portfolio vision, and long-term financial targets. This signals a period of major strategic review that will define future investments and priorities. |
Signal API · MCP
Track Medtronic with the Signal API
One POST /v1/companies/enrich call with medtronic.com returns Medtronic 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"medtronic.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Medtronic 10-Q
When did Medtronic file its latest 10-Q?
What did Medtronic disclose in its latest 10-Q?
What did Medtronic say on its recent earnings calls?
Where can I read Medtronic's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .